Anti-Human Siglec-3/CD33 Recombinant Nanobody (SAA2052) (HB185013)

Name: Anti-Human Siglec-3/CD33 Recombinant Nanobody (SAA2052)
Brand: abinScience
SKU: HB185013
Price: 191 USD
Availability: InStock

Даташит Поделиться продуктом Копировать информацию

Цена(USD):

Спецификация:

50ug
100ug
1mg

Количество:

Свяжитесь с нами

Обзор
Изображения
Ссылки
Даташит
SDS

Обзор

Каталожный номер

HB185013

Бренд

abinScience

Описание

Anti-Human CD33 Nanobody (SAA2052) [SAA2052] (HB185013) is a alpaca monoclonal antibody detecting CD33 in ELISA, FCM. Suitable for Human and Cynomolgus.

Highlights

●Flow Cytometry — Validated for flow cytometry applications.

Реактивность видов

Human, Monkey

Применения

ELISA, FCM, WB

Хозяинский вид

Alpaca

Клоональность

Monoclonal

Изотип

VHH-8His-Cys-tag

ID клона

SAA2052

Проверенные приложения

Цель

Myeloid cell surface antigen CD33, Sialic acid-binding Ig-like lectin 3, Siglec-3, CD33, gp67, SIGLEC3

Уровень эндотоксинов

Please contact with the lab for this information.

Чистота

>95% as determined by SDS-PAGE.

Очистка

Purified by Nickel column.

Номер доступа

P20138

Форма

Liquid

Буфер хранения

0.01M PBS pH 7.4

Пожалуйста, обратитесь к конкретной информации о буфере в печатной версии даташита или в индивидуальном сертификате качества (COA) для партии.

Информация об использовании продукта

Применение	Разбавление
ELISA	1:2000-1:20000
WB	1:500-1:2000

Устойчивость и хранение

Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.

Фон

Myeloid cell surface antigen CD33 is a ~39 kDa protein. Sialic-acid-binding immunoglobulin-like lectin (Siglec) that plays a role in mediating cell-cell interactions and in maintaining immune cells in a resting state. Preferentially recognizes and binds alpha-2,3- and more avidly alpha-2,6-linked sialic acid-bearing glycans. Upon engagement of ligands such as C1q or syalylated glycoproteins, two immunoreceptor tyrosine-based inhibitory motifs (ITIMs) located in CD33 cytoplasmic tail are phosphorylated by Src-like kinases such as LCK. These phosphorylations provide docking sites for the recruitment and activation of protein-tyrosine phosphatases PTPN6/SHP-1 and PTPN11/SHP-2. In turn, these phosphatases regulate downstream pathways through dephosphorylation of signaling molecules. CD33 is the therapeutic target of gemtuzumab ozogamicin (Mylotarg).

1. Vitale, C. et al. (1999) Proceedings of the National Academy of Sciences of the United States of America 96, 15091-6. PMID: 10611343

2. Vitale, C. et al. (2001) Proceedings of the National Academy of Sciences of the United States of America 98, 5764-9. PMID: 11320212

3. Lajaunias, F. et al. (2005) European journal of immunology 35, 243-51. PMID: 15597323

4. Freeman, SD. et al. (1995) Blood 85, 2005-12. PMID: 7718872

5. Paul, SP. et al. (2000) Blood 96, 483-90. PMID: 10887109

6. Son, M. et al. (2017) Scientific reports 7, 270. PMID: 28325905

7. Taylor, VC. et al. (1999) The Journal of biological chemistry 274, 11505-12. PMID: 10206955

8. Ulyanova, T. et al. (1999) European journal of immunology 29, 3440-9. PMID: 10556798

Примечание

For research use only.

Изображения

SDS-PAGE

SDS-PAGE for Anti-Human CD33 Recombinant Nanobody (SAA2052)
Bioactivity

Detects CD33 (Catalog No: HB185011) in indirect ELISA.
Western blot

Western blot analysis was performed using anti-CD33 monoclonal antibody at 1ug/mL on various samples.
Lane 1: recombinant human CD33 (Catalog No: HB185011)